Navigation Links
Accuray Announces Results for Second Quarter Fiscal 2010
Date:2/4/2010

taxes (696) 31 (557) 85 ---- -- ---- -- Net income (loss) $(1,176) $1,350 $(4,452) $(1,829) ======= ====== ======= ======= Net income (loss) per common share, basic and diluted: Basic $(0.02) $0.02 $(0.08) $(0.03) Diluted $(0.02) $0.02 $(0.08) $(0.03) Weighted average common shares outstanding used in computing net income (loss) per share: Basic 57,405 55,064 57,112 54,845 Diluted 57,405 58,267 57,112 54,845 Cost of revenue, selling and marketing, research and development, and general and
'/>"/>
SOURCE Accuray Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Accuray Incorporated to Report Financial Results for First Quarter of Fiscal 2010
2. Accuray Incorporated to Present at 20th Annual Oppenheimer Healthcare Conference
3. Accuray Ranked 155th Fastest Growing Company in North America on Deloittes 2009 Technology Fast 500(TM)
4. Accuray Announces Regionalized Management Strategy for Americas
5. Accurays Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers
6. Accuray Introduces the CyberKnife(R) VSI(TM) System
7. Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2010
8. Accuray Hires General Manager for Japan
9. Accuray Incorporated to Present at 28th Annual J. P. Morgan Healthcare Conference
10. Accuray Incorporated to Present at Piper Jaffray Healthcare Conference and J. P. Morgan Small/Mid Cap Conference
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... MENLO PARK, Calif. , May 29, ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies in new orphan drug indications, presented additional ... Cancer Research (AACR) Advances in Brain Cancer Research ... product candidate VAL-083 (dianhydrogalactitol) to treat ...
(Date:5/29/2015)... OAKS, Calif. , May 29, 2015 /PRNewswire/ ... pooled data from two pivotal Phase 3, global, ... calcimimetic, for the treatment of secondary hyperparathyroidism (SHPT) ... hemodialysis. Both studies met the primary endpoint, demonstrating ... AMG 416 groups achieved a greater than 30 ...
(Date:5/28/2015)... , May 28, 2015  Eli Lilly and Company ... its previously announced cash tender offer for up to $1.6 ... securities. Holders of notes who tendered, and did ... New York City time, on May ... for purchase by Lilly, are eligible to receive the total ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... (Nasdaq: MYL ) today confirmed that the ... Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation in connection with ... with the U.S. Food and Drug Administration (FDA) for ... 0.05 mg/day, 0.075 mg/day and 0.1 mg/day. This product ...
... would tax the companies that manage prescription drug benefits ... owners they contract with – will drive up prescription ... Management Association (PCMA), the trade group for America,s pharmacy ... of America,s businesses, state and federal government agencies, and ...
Cached Medicine Technology:Mylan Confirms First-to-File Patent Challenge Relating to Vivelle-Dot® 2PCMA: Mississippi's 'Secret Prescription Drug Tax' Will Raise Costs 2
(Date:5/29/2015)... Washington, PA (PRWEB) May 29, 2015 ... ” quiz-based learning in 14 medical specialties, now offers ... includes a wide spectrum of rheumatology disorders ranging from ... Alfred Saint Jacques, editorial director of MDLinx, and Caroline ... excited about the impact it will have on the ...
(Date:5/29/2015)... May 29, 2015 The Recovery ... substance abuse, and co-occurring mental health treatment facility, ... cutting for the general public on June 1st, ... The Recovery Village at Palmer Lake will offer ... programming, utilizing traditional and evidence-based therapies, in a ...
(Date:5/29/2015)... On May 21, 2015, Elle Magazine in article titled ... Botox ?” reported on the four most commonly searched beauty ... to determine these results and then sought expert help to ... example, is how to keep neck skin tight . ... the appropriate age to start receiving Botox injections . ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Johnson ... reached a confidential Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) ... gynecomastia due to his use of the antipsychotic ... been selected for the third bellwether trial to ... tort litigation underway in Pennsylvania’s Philadelphia Court of ...
(Date:5/29/2015)... 2015 Intermountain Healthcare of ... Stratus Video Interpreting for on-demand ... communication and timely care for patients with ... Stratus’ video remote interpreting (VRI) services will ... to quickly access qualified medical interpretation in ...
Breaking Medicine News(10 mins):Health News:MDLinx Launches Smartest Rheumatologist 2Health News:Advanced Recovery Systems Announces the Opening of The Recovery Village at Palmer Lake 2Health News:Botox, Wrinkles and Double Chins: The Most-Asked Beauty Problems According to Google 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4
... National ... Immunization Awareness Month, NORTH HAVEN, Conn., Sept. 6 In ... in,Connecticut is reminding parents to make sure their adolescents,immunizations are up ... the perfect time for parents to check with their child,s provider,to ...
... Hospital Directory show new rules issued by the Centers, for ... rural hospitals and hospitals specializing in cardiac care. ... changes in outlier payment are also forecasted., ... Services (CMS) has issued the most sweeping rule,changes for hospital ...
... IV product a proven treatment -, BELLEVILLE, ... (TSX: BNC), a research-based, technology-driven Canadian,biopharmaceutical company, today ... to Australia in order to be able to ... that continent,s equine influenza outbreak.,The outbreak began in ...
... of women with breast cancer stopped taking a commonly ... to a new study from researchers at the University ... the study were taking aromatase inhibitors, a type of ... fuels some breast cancers. The treatment is generally given ...
... LOUISVILLE, Ky., Sept. 5 Ventas, Inc. (NYSE:,VTR) ("Ventas" ... Directors,declared a regular quarterly dividend of $0.475 per share, ... record on September 17, 2007. The,dividend is the third ... dividend. Ventas, Inc. is a leading healthcare real ...
... a,wholly owned subsidiary of Siemens Corporation, announced today that ... offer for all outstanding,shares of common stock of Dade ... has been extended to 12:00 Midnight, New York City ... being made pursuant to,an Agreement and Plan of Merger, ...
Cached Medicine News:Health News:Immunizations Part of Back to School Preparations 2Health News:Immunizations Part of Back to School Preparations 3Health News:Just Completed Studies Reveal Impact of New Medicare Reimbursement Regulations 2Health News:Bioniche Responds to Australian Equine Influenza Outbreak 2Health News:Bioniche Responds to Australian Equine Influenza Outbreak 3Health News:13 percent of women stop taking breast cancer drug because of side effects, U-M study finds 2Health News:13 percent of women stop taking breast cancer drug because of side effects, U-M study finds 3Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 2Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 3Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 4Health News:Siemens Extends Tender Offer for Acquisition of Dade Behring 2
... patented Miami J® collar is designed to ... patient. Break-through fabrics inhibit decubitus during long-term ... and speed recovery. And the unique ... any prefabricated extended wear collar. And kids ...
One-piece rigid cervical collar is designed to fit securely around the neck and mandible to provide immobilization and support of the cervical region...
Model C-10 is a four post cervical orthosis which controls flexion, extension, lateral flexion, rotation, and axial motion. Each post may be individually adjusted in height....
... Orthosis ensures comfort and immobilization ... anterior frame and occipital component. ... flow and easy application. Large ... For added comfort, removable, flannel-covered, ...
Medicine Products: